Slower cancer growth after venetoclax-rituximab treatment in patients with CLL
Professor Arnon P. Kater and his fellow investigators presented a new model to report kinetics of MRD (minimal residual disease) after end of treatment in patients with CLL at ASH 2021. In this MEDtalk, Professor Kater reveals the results that suggest a slower cancer growing (MRD-level) after venetoclax-rituximab treatment compared with bendamustine-rituximab treatment, in patients with CLL.
Get access to the article
If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.